Please note, this OEL/ADE monograph also applies to rebamipide nicotinamide (CAS RN Not Available) and Sodium hydroxide rebamipide (CAS RN Not Available). Rebamipide is a quinolinone derivative with antiulcer and anti-inflammatory activities. Orally, rebamipide is indicated for the treatment of gastric mucosal lesions (erosions, bleeding, redness and edema) in the conditions of acute gastritis, acute exacerbation of chronic gastritis, and gastric ulcers. Rebamipide has also been studied in combination therapy for the eradication of Helicobacter pylori infection. Rebamipide ophthalmic suspension is also used to treat dry eye.
Affygility Solutions has an occupational exposure limit (OEL) and control band assignment for this active pharmaceutical ingredient (API). This monograph also contains the acceptable daily exposure (ADE) value.
OEL Fastrac monographs are a cost-effective and convenient way to meet the requirements for PDEs (ADEs) contained in the EMA Guideline on setting health based exposure limits for use in risk identification in the manufacture of different medicinal products in shared facilities (EMA/CHMP/CVMP/SWP/169430/2012), as well as PIC/S and ANVISA requirements, and to obtain the following information:
To order an OEL/ADE monograph for Rebamipide, just click the ADD TO CART button.
If you're wondering about HBEL, we have something for you.
Not the compound you were looking for? You can search the OEL Fastrac catalog to find more available compounds.
Affygility Solutions’ OEL Fastrac service is an user-friendly system that enables us to make confident decisions and focus on moving the compound safely through our facility. We can quickly access the database to determine if a new drug is within the OEL Fastrac library, and if so, immediately download a detailed OEL banding report. The OEL Fastrac system has been a helpful tool in our overall EH&S program.